| Description | This product is a neutralizing antibody that binds to Severe Acute Respiratory Syndrome Coronavirus 2. AZD1061 have strong neutralizing activity against SARS-CoV-2 and variants of concern with antigenic substitutions in the RBD.AZD1061 neutralize the virus by blocking RBD access to the human receptor ACE2. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 |
| Epitope | RBD receptor binding domain |
| Isotype | IgG1 |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA |
| Application Notes | Wells of 384-well microtiter plates were coated with purified recombinant SARS-CoV-2 S 6P protein at 4°C overnight. Plates were blocked with 2% non-fat dry milk and 2% normal goat serum in DPBS containing 0.05% DPBS-T for 1 h. Antibodies were diluted to 10 µg/mL and titrated two-fold 23 times in DPBS-T and added to the wells, followed by an incubation for 1 h at room temperature. After washing with DPBS-T, a goat anti-human IgG secondary antibody conjugated with horseradish peroxidase was added and incubated for one hour. Plates were then washed with DPBS-T and TMB substrate was added to each well. Reactions were quenched with 1 M hydrochloric acid and absorbance was measured at 450 nm using a spectrophotometer. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | SARS-CoV-2 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
